Mar 30,2022

Terumo, Glooko partner for diabetes data sharing with insulin patch pump

Terumo (TSE:4543) and Glooko today announced a collaboration to integrate their technologies and create new diabetes data sharing solutions. In the new technology integration, users with diabetes will be able to transfer recorded data from the Terumo Medisafe With insulin patch pump into the Glooko management platform, allowing for the visualization of insulin dosage, food and activities.

COLLABORATION PARTNERSHIP

#connected device

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Mar 30,2022

Analysts say high payor coverage, increased CGM adoption bodes well for Abbott Diabetes Care Diabetes Care, Dexcom

Analysts have suggested that companies like Abbott Diabetes Care Diabetes Care (NYSE:ABT) and Dexcom (Nasdaq:DXCM) may benefit from expected reimbursement progress. BTIG hosted a conference call with North Shore Medical Center (Salem, Massachusetts) Medical Director Dr. Gary Cohen and Healthcare Analytics, LLC analyst and consultant Dr. Joshua Cohen. The two experts offered insights into prescriber and patient interest in continuous glucose monitors (CGMs) among type 2 diabetes non-intensive insulin therapy (T2 NIIT) patients.

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 31,2022

Alberto Mas Announces Intent to Retire from BD at End of Fiscal Year

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD. Mas, 60, is currently executive vice president and president of the Medical segment for BD, a position he has held since May 2018 .

View Analyst & Ambassador Comments
Go to original news
Mar 31,2022

Dexcom Schedules First Quarter 2022 Earnings Release and Conference Call for April 28, 2022 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022.

View Analyst & Ambassador Comments
Go to original news
Apr 12,2022

Rimidi Named to AVIA Connect’s Top 50 Companies in Remote Patient Monitoring Report

Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives, announced today that it was recognized as a Top 50 Company in remote monitoring by AVIA Connect, the leading digital health marketplace.

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 20,2022

Focus on digital health: The trend for more health awareness in everyday life

The new "beurer HealthManager Pro" app and other innovations will be presented at the Appsfactory stand at the DMEA in Berlin from April 26th to 28th, 2022

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 01,2022

BD completes spinoff of Embecta diabetes company

BD (NYSE:BDX) announced today that the planned spinoff of its diabetes business — named Embecta (Nasdaq:EMBC)— has been made official.

View Analyst & Ambassador Comments
Go to original news
Apr 01,2022

Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System, to Its Range of Scan-Free and Fingerprick†-Free Devices

DexCom, Inc. (NASDAQ:DXCM) announced today the new DexCom ONE Continuous Glucose Monitoring System will launch in the United Kingdom this May.

PRODUCT

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 04,2022

Better Therapeutics to Participate in Chardan’s Virtual Prescription Digital Therapeutics Summit

Better Therapeutics, Inc. (NASDAQ: BTTX), today announced that Kevin Appelbaum, Co-Founder and CEO, will participate in a fireside chat at Chardan's Virtual Prescription Digital Therapeutics Summit on Monday, April 11, 2022 at 1:30 p.m. Eastern Time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 04,2022

Diabetes Reversal Leader Virta Health Earns Validation Institute’s Highest Ranking for Delivering Industry-Leading Prescription Drug Savings

Virta Health, the leader in type 2 diabetes reversal, earned the Validation Institute’s most prominent, Level 1 savings validation for delivering unmatched medication cost reductions. Per the analysis, Virta’s validated prescription drug savings amounted to nearly $6k per patient over a two-year period.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES